Results 41 to 50 of about 15,932 (195)

Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism, 2015
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and ...
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas   +4 more
doaj   +1 more source

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

Journal of Diabetes Investigation, 2020
Aims/Introduction Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator ...
Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara   +5 more
doaj   +1 more source

Nine‐Year Follow‐Up After M‐TEER for Secondary Mitral Regurgitation in a Patient With Cardiogenic Shock

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter edge‐to‐edge repair (TEER) has become an established therapeutic option for patients with severe secondary mitral regurgitation (SMR). While randomized trials and registry data have reported outcomes up to 5 years, longer follow‐up data remain scarce.
Tobias Reithmayer, Thomas J. Stocker, Ludwig T. Weckbach, Julia Novotny, Philipp M. Doldi, Hannah Kempton, Steffen Massberg, Michael Näbauer, Jörg Hausleiter, Lukas Stolz   +9 more
wiley   +1 more source

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice

Kidney & Blood Pressure Research
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors target SGLT2 in renal proximal tubules and promote glycosuria in type 2 diabetes mellitus in humans and animal models, resulting in reduced blood glucose levels.
Jin Joo Cha, Hye-jin Park, Ji Ae Yoo, Jungyeon Ghee, Dae Ryong Cha, Young Sun Kang   +5 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels

Heliyon, 2022
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that, in addition to glucose reduction, lowers systemic blood pressure. Here, we investigated if dapagliflozin could directly relax small mesenteric arteries that control peripheral ...
Ahasanul Hasan, Sreelakshmi N. Menon, Farzana Zerin, Raquibul Hasan   +3 more
doaj   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Dapagliflozin-induced abnormal uterine bleeding in a patient with dilated cardiomyopathy and chronic heart failure: a case report

Journal of International Medical Research
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are extensively used in the management of heart failure because of their cardiovascular benefits. Adverse drug reactions associated with dapagliflozin include diabetic ketoacidosis, fungal infections, and
Shikun Gong, Shunan Zhang, Yun Ye, Meiling Wu   +3 more
doaj   +1 more source